Skip to main content
SpringerLink
Log in

Transient protein folding in condensates reveals ways to target disordered oncoproteins

  • Research Briefing
  • Published:

From Nature Structural & Molecular Biology

View current issue Submit your manuscript

The androgen receptor forms nuclear condensates associated with gene transcription. Investigating the molecular basis of condensate formation led us to discover an approach for optimizing small molecules that inhibit the receptor in a currently untreatable form of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: The androgen receptor forms nuclear condensates enriched in transiently stable secondary structures that are targetable with small molecules.

References

  1. Bradner, J. E., Hnisz, D. & Young, R. A. Transcriptional addiction in Cancer. Cell 168, 629–643 (2017). This review describes various mechanisms of transcriptional dysregulation in cancer.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Biesaga, M., Frigolé-Vivas, M. & Salvatella, X. Intrinsically disordered proteins and biomolecular condensates as drug targets. Curr. Opin. Chem. Biol. 62, 90–100 (2021). This review describes insights and challenges of targeting intrinsically disordered proteins with small molecules.

    Article  CAS  PubMed  Google Scholar 

  3. Tomura, A. et al. The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein. J. Biol. Chem. 276, 28395–28401 (2001). This paper reported hormone-dependent speckle formation by the androgen receptor.

    Article  CAS  PubMed  Google Scholar 

  4. Andersen, R. J. et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17, 535–546 (2010). This paper reports the identification of EPI-001 from a phenotypic screen, active against castration-resistant prostate cancer.

    Article  CAS  PubMed  Google Scholar 

  5. De Mol, E. et al. EPI-001, a compound active against castration-resistant prostate cancer, targets Transactivation Unit 5 of the androgen receptor. ACS Chem. Biol. 11, 2499–2505 (2016). This paper reports NMR data on the binding of EPI-001 to an intrinsically disordered sub-domain of the androgen receptor.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Basu, S. et al. Rational optimization of a transcription factor activation domain inhibitor. Nat. Struct. Mol. Biol. https://doi.org/10.1038/s41594-023-01159-5 (2023).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Transient protein folding in condensates reveals ways to target disordered oncoproteins. Nat Struct Mol Biol 30, 1836–1837 (2023). https://doi.org/10.1038/s41594-023-01160-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41594-023-01160-y

  • Springer Nature America, Inc.

Search

Navigation